Noninvasive options for ‘wearing-off’ in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists-Reference-Cited by-同舟云学术

Noninvasive options for ‘wearing-off’ in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists

Published:2018-10 Issue:5 Volume:8 Page:349-360
ISSN:1758-2024
Container-title:Neurodegenerative Disease Management
language:en
Short-container-title:Neurodegenerative Disease Management

Author:

Fackrell Robin¹,Carroll Camille B²,Grosset Donald G³,Mohamed Biju⁴,Reddy Prashanth⁵,Parry Miriam⁵,Chaudhuri Kallol Ray⁶,Foltynie Tom⁷

Affiliation:

1. Department of Geriatric Medicine, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK

2. Faculty of Medicine & Dentistry, University of Plymouth, Plymouth, UK

3. Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, UK

4. Department of Medicine and Gerontology, University Hospital of Wales, Cardiff, UK

5. Department of Clinical Gerontology, King's College Hospital NHS Foundation Trust, London, UK

6. Institute of Psychiatry, Psychology & Neuroscience at King's College & Parkinson Foundation International Centre of Excellence, King's College Hospital NHS Foundation Trust, London, UK

7. Unit of Functional Neurosurgery at UCL Institute of Neurology and the National Hospital for Neurology & Neurosurgery, London, UK

Abstract

In the past 4 years, two adjunctive treatment options to levodopa have been licensed for use in the UK in patients with Parkinson's disease (PD) and motor fluctuations: opicapone, a third-generation catechol-O-methyl transferase inhibitor, and safinamide, a monoamine oxidase B inhibitor. This clinical consensus outlines the practical considerations relating to motor fluctuations and managing wearing-off in patients with PD, and provides a clinical insight to adjunctive treatment options, including opicapone and safinamide. Practice-based opinion was provided from a multidisciplinary steering Group of eight UK-based movement disorder and PD specialists, including neurologists, geriatricians and a nurse specialist, from England, Scotland and Wales.

Publisher

Future Medicine Ltd

Subject

Clinical Neurology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/nmt-2018-0020

Reference69 articles.

1. The second brain and Parkinson’s disease

2. National Institute for Health and Care Excellence. Parkinson's disease in adults: diagnosis and management (2017). www.nice.org.uk/guidance/ng71/evidence/full-guideline-pdf-4538466253.

3. Are men at greater risk for Parkinson's disease than women?

4. Parkinson's UK. The incidence and prevalence of Parkinson's in the UK (2018). www.parkinsons.org.uk/sites/default/files/2018-01/CS2960Incidenceandprevalencereportbrandingsummaryreport.pdf.

5. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Addressing Comorbidities in People with Parkinson’s Disease: Considerations From An Expert Panel;Journal of Parkinson's Disease;2024-01-23

2. An Exploration of Wearable Device Features Used in UK Hospital Parkinson Disease Care: Scoping Review;Journal of Medical Internet Research;2023-08-18

3. The Dashboard Vitals of Parkinson’s: Not to Be Missed Yet an Unmet Need;Journal of Personalized Medicine;2022-12-02

4. An Exploration of Wearable Device Features Used in UK Hospital Parkinson Disease Care: Scoping Review (Preprint);2022-09-25

5. Absorption, metabolism and excretion of opicapone in human healthy volunteers;British Journal of Clinical Pharmacology;2022-05-20